

ASPREE recently welcomed to SPHPM their US collaborators from the Berman Center for Outcomes and Clinical Research, and guests from the National Cancer Institute (NCI), to discuss the progress and future of the ASPREE trial and sub-studies.

The principal ASPREE trial, which is investigating low-dose aspirin and disease prevention in 19,114 older people (16,703 in Australia), is due to conclude at the end of 2017.

Approximately 80 national and international senior researchers are collaborating on the principal ASPREE trial and/or an ASPREE sub-study.

ASPREE sub-studies include: ACES (aspirin and cancer); ALSOP - questionnaires identifying medical and social factors that may affect the ability to age well; ASPREE-AMD (aspirin and age-related macular degeneration); ASPREE-ANTISEPSIS (aspirin and severe infection); ASPREE-D (aspirin and depression); ASPREE- FRACTURES (aspirin and falls and fractures); ASPREE-HEARING (aspirin and age-related hearing loss); ASPREE-Knee (aspirin and osteoarthritis); ASPREE-NEURO (aspirin and microvascular bleeds in the brain); ENVIS-ion – changes in retinal and brain vasculature and SNORE-ASA (aspirin and obstructive sleep apnoea). The ASPREE Healthy Ageing Biobank, which is collecting 3 year follow-up samples, is a repository for biological indicators of health (or disease). Two genomic sub-studies are in collaboration with the Garvan Institute of Medical Research and the Mount Sinai School of Medicine in New York. Two new sub-studies are investigating the effect of androgens on cardiovascular health and mortality in ASPREE women, and measuring levels of inflammatory biomarkers in plasma from ASPREE participants.

Recent NHMRC grants will fund the completion of the ASPREE trial and further investigate the effect of low-dose aspirin on colorectal cancer in older people.

www.aspree.org @aspree_au

Pictured below: The ASPREE team welcomed to SPHPM, their US collaborators from the Berman Center for Outcomes and Clinical Research and guests from the National Cancer Institute (NCI) recently.



Back row (from left) Prof Mark Nelson, A/Prof Robyn Woods (ASPREE Exec Officer), Prof Danny Liew, Dr Jessica Lockery, Dr Suzanne Orchard, Dr Sharyn Fitzgerald, Dr Emily Parker, Dr Andrew Haydon.

Front row (from left) Dr Paul Lacaze, Prof Chris Reid, Dr Leslie Ford (NCI), Prof Anne Murray (Berman), Prof John McNeil, Dr Asad Umar (NCI), A/Prof Andrew Chan, Massachusettes General Hospital, Prof Colin Johnston, Ms Brenda Kirpach (Berman), Dr Carlene Britt, Prof Rory Wolfe, Ms Megan Dumas.